Large-scale Production & Purification Of Compounds With

生物技术股负责生物材料的生产和提纯。该股承担广泛的生物生产任务，例如大规模生长原核生物和真核生物，以及生产和提纯生物化合物，特别是蛋白质。这些产品无法从商业渠道获得，但需要用于临床和结构研究。生物技术股有能力通过实施生理和技术方法来处理这些不同的生产任务。由于该股拥有两个综合要素：一个全面运作的多用途试生产设施和进行研究和工艺开发的能力，因此有可能进行有效的工艺开发和生产。在过去的一年里，该单位进行了近200种不同的生产准备，包括：1)培养各种微生物，如重组大肠杆菌、重组毕赤酵母、酵母、白喉棒状杆菌突变株和炭疽杆菌突变株；2)大量繁殖哺乳动物细胞，如HeLa，CHO，HEK 293，昆虫细胞，如SF9和HI5；3)从杂交瘤细胞和兔血清中纯化克数量的重组铜绿假单胞菌外毒素、炭疽杆菌保护性抗原、C型葡萄球菌肠毒素、重组疟疾蛋白CSP、艰难氯杆菌毒素A、重组脂联素以及多种杂交瘤细胞和兔血清抗体。在研究和开发方面，该单位开展了以下专题的工作：1)继续开发更有效的大规模蛋白质回收方法，继续利用新型膨胀柱实施扩展床吸附技术：该柱没有流动适配器和筛子，因此可以以较高的低速率处理较大浓度的生物量；2)继续其旨在了解各种重组大肠杆菌菌株葡萄糖代谢的研究，以努力找出为什么某些菌株更适合利用微阵列技术和蛋白质分析来生产外来蛋白质；3)继续其与哺乳动物细胞相关的研究项目，旨在了解可以在悬浮中生长的细胞和依赖锚定的细胞之间的遗传差异。4)与LDMI、NICHD合作，该单位继续开发针对福氏志贺氏菌和炭疽杆菌的新疫苗，产品目前处于临床试验中。5)该单位继续其丝状真菌生产重组蛋白的研究和开发项目。6)启动了一项新的研究和开发项目，旨在生产质粒DNA。

The Biotechnology Unit is responsible for the production and purification of biological material. The Unit undertakes a wide array of biological production tasks such as large scale growth of prokaryotes and eucaryotes, and production and purification of biological compounds especially proteins. These products, not available from commercial sources, are needed for clinical and structural studies. The Biotechnology Unit is capable of handling these various production tasks by implementing both physiological and technical approaches. Efficient process development and production is possible since the Unit possesses two integrated elements: a fully operational multi purpose pilot production facility and the capability of conducting research and process development. During the last year the unit performed approximately 200 different, production preparations including: 1) growing various microorganisms such as recombinant Escherichia coli, recombinant Pichia pastoris, yeasts, mutant strain of Corynebacteria diphtheria and mutant strain of Bacillus anthracis; 2) propagating large volumes of mammalian cells such as HeLa, CHO, HEK 293, insects cells such as Sf 9 and hi five; 3) purifying gram quantities of recombinant Pseudomonas aeruginosa exotoxin A, protective antigen from Bacillus anthracis, Staphylococcal enterotoxin type C, recombinant malarial protein CSP, Chlostridium difficile toxin A, recombinant adiponectin and several antibodies from hybridoma cultures and rabbit serum. On the research and development arena, the unit conducted work in the following topics: 1) Continued the development of more efficient methods for large scale protein recovery, work was continued on the implementation of expanded bed adsorption techniques utilizing new types of expanded column: this column does not have flow adaptors and screens and therefore can handle larger concentration of biomass at higher low rates; 2) continued its research aimed at understanding the glucose metabolism of various recombinant E. coli strains in an effort to find out why certain strains are more suitable for foreign protein production using microarrays technology and protein analysis; 3) continued its research project associated with mammalian cells aiming at understanding the genetic difference between cells that can grow in suspension, and cells that are anchorage dependent. 4) In collaboration with LDMI, NICHD, the unit continued the work on the development of new vaccine against Shigella flexneri and Bacillus anthracis, the products are currently in clinical trials.5) the unit continued its research and development project on the production of recombinant proteins from filamentous fungi. 6) A new research and development project aiming at the production of plasmid DNA was initiated.